Company Ceases Manufacture of Death Penalty Drug
Get the world’s most fascinating discoveries delivered straight to your inbox.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
Hospira Pharmaceuticals, the only American manufacturer of a drug used in U.S. executions, will cease making that drug, the company announced today.
Sodium thiopental, an anesthesia drug, is used to put inmates to sleep before two other drugs paralyze the muscles and stop the heart. There has been a shortage of sodium thiopental recently, forcing states to scramble for alternatives or delay executions. Hospira said a supply issue with the drug's active ingredient was to blame for the shortage. [Read Execution Science: What's the Best Way to Kill a Person?]
The company had planned to move manufacture of the product, known as Pentothal, from North Carolina to its plant in Italy. Hospira spokesman Daniel Rosenberg told LiveScience the move was because the Italian facility had a state-of-the-art sodium thiopental production line. But Italian authorities objected to the drug's use in executions and insisted that Hospira prevent the drug's use in capital punishment. (Italy does not allow the death penalty.)
The Italian negotiations were not a contributing factor to the drug's previous shortage, Rosenberg told LiveScience.
Hospira has regularly voiced its own disapproval of the drug's use in the death penalty, arguing that it is a drug with legitimate medical uses. The company sells primarily to wholesalers, and said in a statement that it cannot control how customers use the drug.
"Based on this understanding, we cannot take the risk that we will be held liable by the Italian authorities if the product is diverted for use in capital punishment," the statement read. "Exposing our employees or facilities to liability is not a risk we are prepared to take."
The cease in manufacturing is likely to cause more difficulties for states trying to execute prisoners. All of California's supply of sodium thiopental expired Oct. 1. Arizona, Kentucky, Ohio and Oklahoma have also experienced sodium thiopental shortages. On Dec. 16, Oklahoma inmate John David Duty became the first person in the United States whose execution involved pentobarbital, a drug usually used to euthanize animals.
Get the world’s most fascinating discoveries delivered straight to your inbox.
You can follow LiveScience Senior Writer Stephanie Pappas on Twitter @sipappas.

Stephanie Pappas is a contributing writer for Live Science, covering topics ranging from geoscience to archaeology to the human brain and behavior. She was previously a senior writer for Live Science but is now a freelancer based in Denver, Colorado, and regularly contributes to Scientific American and The Monitor, the monthly magazine of the American Psychological Association. Stephanie received a bachelor's degree in psychology from the University of South Carolina and a graduate certificate in science communication from the University of California, Santa Cruz.
